Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cabaletta Bio, Inc. - Common Stock (NQ:CABA)

2.525 -0.215 (-7.85%)
Streaming Delayed Price Updated: 2:27 PM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cabaletta Bio, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Cabaletta Bio Announces Pricing of Public Offering of Common Stock
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces Proposed Public Offering of Common Stock
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 5/2
Via Investor Brand Network
Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Receives FDA Fast Track Designation for CABA-201
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference
From Cabaletta Bio
Via GlobeNewswire
Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus’ Safety Switch System in Cell Therapies for Autoimmune Disease
From Autolus Therapeutics plc
Via GlobeNewswire
Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces $35 Million Offering
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy
From Cabaletta Bio
Via GlobeNewswire
NASDAQ:CABA Long Term Investor Alert: Investigation over Potential Wrongdoing at Cabaletta Bio, Inc.
San Diego, CA -- (SBWIRE) -- 06/17/2022 -- Certain directors of Cabaletta Bio, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Deadline Today Reminder: The Schall Law Firm Encourages Investors in Cabaletta Bio, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Deadline Today Alert: The Schall Law Firm Encourages Investors in Cabaletta Bio, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Deadline Tomorrow Reminder: The Schall Law Firm Encourages Investors in Cabaletta Bio, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
CABALETTA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Cabaletta Bio, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Reminds Cabaletta Bio, Inc. (CABA) Investors of Class Action Deadline and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
CABA SHAREHOLDER ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Cabaletta Bio, Inc. Investors to Secure Counsel Before Important April 29 Deadline in Securities Class Action - CABA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cabaletta Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - CABA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cabaletta Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - CABA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cabaletta Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CABA
From The Rosen Law Firm, P.A.
Via Business Wire
CABA Stock Investigation: Robbins LLP Investigates Cabaletta Bio, Inc. (CABA) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.